Silvia Cascini, PhD, senior researcher at the Department of Epidemiology of the Lazio Regional Health Service, Rome, Italy, conducted the study using routinely collected, high quality data coming from regional health administrative databases. This data source, more and more used in the field of epidemiology, has been integrated with information registered on the ad hoc platform implemented during the COVID-19 outbreak for surveillance purposes.
Dr. Cascini said: “Previous studies reported that people with dementia are more likely to contract SARS-CoV-2 infection than people without and that dementia is in itself a risk factor for COVID-19-related mortality. However, there was still little knowledge about individual factors increasing the risk of SARS-CoV-2 infection and mortality in this particularly fragile population”.
The study included 37,729 adults with dementia aged 65+ and was carried out in the Lazio region, located in central Italy, including Rome, and with about 6,000,000 inhabitants. During 2019, 2,548 (about 7%) of individual with dementia get the infection and 626 died within 60 days from the infection. Dr. Cascini believes that this is the first population-based cohort study including a large sample size addressing the determinants of SARS-CoV-2 infection and death from COVID-19 among patients with dementia.
The research found that the risk of infection and mortality is markedly higher in people with dementia as compared with general elderly population. A high burden of comorbidities, such as blood, cerebrovascular and respiratory diseases, anxiety, history of hip fracture, and antipsychotic use have been identified as risk factors for both infection and mortality, while severity of symptoms at diagnosis and male gender are specifically associated with an increased risk of COVID-19-related death.
“Our analysis revealed a strong association between presence of symptoms at diagnosis and short-term mortality,” said Nera Agabiti, PhD. “We have to keep in mind that although much has been learned about how to prevent the infection, elderly with dementia require to be adequately monitored by both physicians and caregivers to minimize exposure to the virus, recognize timely signs/symptoms of COVID-19, and ensure proper disease management.” Considering that the onset of COVID-19 disease in individuals with dementia often occurs with non-respiratory symptoms, such as delirium or functional decline, the Authors underlined the need of close monitoring of dementia patients with suspected COVID-19, for early diagnosis and treatment.
“Since the pandemic continues to influence our lives and threaten population health, in particular that of frail people, the identification of risk factors for SARS-CoV-2 infection and mortality in patients with dementia appeared to be a key aspect to support clinical decisions and public health interventions," concluded Anna Maria Bargagli, PhD.
NOTES FOR EDITORS
Full open access study: "Incidence and Outcomes of SARS-CoV-2 Infection in Older Adults Living with Dementia: A Population-Based Cohort Study" by Silvia Cascini, Nera Agabiti, Claudia Marino, Anna Acampora, Maria Balducci, Enrico Calandrini, Marina Davoli, and Anna Maria Bargagli (DOI: 10.3233/JAD-220369), published in the Journal of Alzheimer’s Disease, Volume 89, Issue 2. The open access article is published by IOS Press and available online at: content.iospress.com/articles/journal-of-alzheimers-disease/jad220369.
For further information, get in touch with Tiziano Costantini at Department of Epidemiology Regional Helth Service, Lazio region, Italy (email@example.com or +39 06 99722126).
About the Journal of Alzheimer’s Disease
Now in its 25th year of publication, the Journal of Alzheimer’s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 4.160 according to Journal Citation Reports (Clarivate, 2022). The journal is published by IOS Press. j-alz.com
About IOS Press
IOS Press is an independent international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in biomedical and life sciences (including neurosciences, medical informatics, cancer research, rehabilitation) and physical sciences (including computer sciences, artificial intelligence, engineering). In addition, we offer specialized services that support scientific advancement. iospress.com